Literature DB >> 34890875

Improving antibody drug development using bionanotechnology.

Emily K Makowski1, John S Schardt2, Peter M Tessier3.   

Abstract

Monoclonal antibodies are being used to treat a remarkable breadth of human disorders. Nevertheless, there are several key challenges at the earliest stages of antibody drug development that need to be addressed using simple and widely accessible methods, especially related to generating antibodies against membrane proteins and identifying antibody candidates with drug-like biophysical properties (high solubility and low viscosity). Here we highlight key bionanotechnologies for preparing functional and stable membrane proteins in diverse types of lipoparticles that are being used to improve antibody discovery and engineering efforts. We also highlight key bionanotechnologies for high-throughput and ultra-dilute screening of antibody biophysical properties during antibody discovery and optimization that are being used for identifying antibodies with superior combinations of in vitro (formulation) and in vivo (half-life) properties.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34890875      PMCID: PMC9356538          DOI: 10.1016/j.copbio.2021.10.027

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   10.279


  55 in total

1.  Direct measurement of protein osmotic second virial cross coefficients by cross-interaction chromatography.

Authors:  Peter M Tessier; Stanley I Sandler; Abraham M Lenhoff
Journal:  Protein Sci       Date:  2004-04-09       Impact factor: 6.725

2.  Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool.

Authors:  Yingda Xu; William Roach; Tingwan Sun; Tushar Jain; Bianka Prinz; Ta-Yi Yu; Joshua Torrey; Jerry Thomas; Piotr Bobrowicz; Maximiliano Vásquez; K Dane Wittrup; Eric Krauland
Journal:  Protein Eng Des Sel       Date:  2013-09-17       Impact factor: 1.650

Review 3.  Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.

Authors:  Miroslav Dostalek; Thomayant Prueksaritanont; Robert F Kelley
Journal:  MAbs       Date:  2017-05-02       Impact factor: 5.857

4.  Cross-interaction chromatography as a rapid screening technique to identify the stability of new antibody therapeutics.

Authors:  Sarah H M Hedberg; Jonathan Rapley; Jonathan M Haigh; Daryl R Williams
Journal:  Eur J Pharm Biopharm       Date:  2018-10-11       Impact factor: 5.571

Review 5.  Drug Development of Therapeutic Monoclonal Antibodies.

Authors:  Diane R Mould; Bernd Meibohm
Journal:  BioDrugs       Date:  2016-08       Impact factor: 5.807

Review 6.  Predictive Screening Tools Used in High-Concentration Protein Formulation Development.

Authors:  Melanie Hofmann; Henning Gieseler
Journal:  J Pharm Sci       Date:  2017-11-02       Impact factor: 3.534

7.  Isolation of state-dependent monoclonal antibodies against the 12-transmembrane domain glucose transporter 4 using virus-like particles.

Authors:  David F Tucker; Jonathan T Sullivan; Kimberly-Anne Mattia; Christine R Fisher; Trevor Barnes; Manu N Mabila; Rona Wilf; Chidananda Sulli; Meghan Pitts; Riley J Payne; Moniquetta Hall; Duncan Huston-Paterson; Xiaoxiang Deng; Edgar Davidson; Sharon H Willis; Benjamin J Doranz; Ross Chambers; Joseph B Rucker
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-16       Impact factor: 11.205

8.  Conformational Chaperones for Structural Studies of Membrane Proteins Using Antibody Phage Display with Nanodiscs.

Authors:  Pawel K Dominik; Marta T Borowska; Olivier Dalmas; Sangwoo S Kim; Eduardo Perozo; Robert J Keenan; Anthony A Kossiakoff
Journal:  Structure       Date:  2015-12-31       Impact factor: 5.006

Review 9.  DNA immunization as a technology platform for monoclonal antibody induction.

Authors:  Shuying Liu; Shixia Wang; Shan Lu
Journal:  Emerg Microbes Infect       Date:  2016-04-06       Impact factor: 7.163

10.  Function-based high-throughput screening for antibody antagonists and agonists against G protein-coupled receptors.

Authors:  Huanhuan Ren; Jian Li; Ning Zhang; Liaoyuan A Hu; Yingli Ma; Philip Tagari; Jianqing Xu; Mei-Yun Zhang
Journal:  Commun Biol       Date:  2020-03-26
View more
  1 in total

1.  Measuring Protein Aggregation and Stability Using High-Throughput Biophysical Approaches.

Authors:  Tristan O C Kwan; Stefan A Kolek; Amy E Danson; Rosana I Reis; Ines S Camacho; Patrick D Shaw Stewart; Isabel Moraes
Journal:  Front Mol Biosci       Date:  2022-05-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.